MoonLake Immunotherapeutics (NASDAQ:MLTX) Short Interest Up 24.3% in January

MoonLake Immunotherapeutics (NASDAQ:MLTX) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 7,182,036 shares, a growth of 24.3% from the December 31st total of 5,776,842 shares. Based on an average trading volume of 5,630,446 shares, the days-to-cover ratio is presently 1.3 days. Currently, 12.7% of the company’s shares are sold short. Currently, 12.7% of the company’s shares are sold short. Based on an average trading volume of 5,630,446 shares, the days-to-cover ratio is presently 1.3 days.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on MLTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a research report on Wednesday, October 8th. Citigroup lowered shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a report on Wednesday, October 29th. BTIG Research raised shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and set a $24.00 price target for the company in a report on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Tuesday. Finally, UBS Group set a $24.00 target price on MoonLake Immunotherapeutics in a report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics presently has a consensus rating of “Hold” and an average target price of $25.77.

MoonLake Immunotherapeutics Stock Down 2.7%

Shares of MoonLake Immunotherapeutics stock traded down $0.42 during trading on Tuesday, reaching $15.37. The stock had a trading volume of 1,071,426 shares, compared to its average volume of 3,510,081. The company has a market capitalization of $987.22 million, a price-to-earnings ratio of -4.63 and a beta of 1.21. The stock has a fifty day moving average price of $14.66 and a two-hundred day moving average price of $27.47. MoonLake Immunotherapeutics has a 52 week low of $5.95 and a 52 week high of $62.75. The company has a current ratio of 8.50, a quick ratio of 8.50 and a debt-to-equity ratio of 0.25.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same period last year, the company posted ($0.56) earnings per share. Sell-side analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, CEO Da Silva Jorge Santos sold 130,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the transaction, the chief executive officer owned 2,948,577 shares in the company, valued at $44,464,541.16. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kristian Reich sold 130,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the completion of the sale, the insider owned 72,908 shares of the company’s stock, valued at approximately $1,099,452.64. The trade was a 64.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 402,908 shares of company stock worth $5,987,162 in the last ninety days. 12.05% of the stock is currently owned by insiders.

Institutional Trading of MoonLake Immunotherapeutics

A number of institutional investors have recently made changes to their positions in the business. Decheng Capital LLC bought a new stake in MoonLake Immunotherapeutics during the 2nd quarter worth about $8,572,000. Jennison Associates LLC bought a new position in shares of MoonLake Immunotherapeutics in the 2nd quarter valued at about $2,941,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of MoonLake Immunotherapeutics in the second quarter valued at about $74,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in MoonLake Immunotherapeutics by 115.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after acquiring an additional 3,166 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB raised its holdings in MoonLake Immunotherapeutics by 360.0% during the third quarter. Rhenman & Partners Asset Management AB now owns 207,000 shares of the company’s stock worth $1,484,000 after acquiring an additional 162,000 shares in the last quarter. Institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.